Literature DB >> 23124003

Comparative quantitative analysis of hepatitis C mutations at amino acids 70 and 91 in the core region by the Q-Invader assay.

Kenichi Tadokoro1, Mariko Kobayashi, Fumitaka Suzuki, Chie Tanaka, Toshikazu Yamaguchi, Makoto Nagano, Toru Egashira, Hiromitsu Kumada.   

Abstract

Hepatitis C virus (HCV) is a major worldwide public health problem, and mutations at amino acids 70 and 91 in the genotype 1b core region predict the effectiveness of combination therapy with peginterferon and ribavirin. An assay based on the Q-Invader technology was developed to determine the relative ratios of the mutant to wild-type virus with high sensitivity. The assay detected a minor type plasmid that constituted only 1% of a mixture of plasmids containing wild-type and mutant sequences. The calculated ratios agreed with those of the template DNA. A total of 123 serum samples of HCV in Japan were examined with the Q-Invader assay. The Q-Invader assay detected all of the mutations that were detected by direct sequencing and even some mutants that direct sequencing could not. PCR with mutant specific primers confirmed those mutations found by the Q-Invader assay and not by direct sequencing. The Q-Invader assay, thus, is a useful tool for detecting mutations at positions 70 and 91 in the HCV-1b core region.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23124003     DOI: 10.1016/j.jviromet.2012.10.011

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Impact of Mutations at Amino Acid 70 in Hepatitis C Virus (HCV) Genotype 1b Core Region on Hepatocarcinogenesis following Eradication of HCV RNA.

Authors:  Norio Akuta; Fumitaka Suzuki; Masahiro Kobayashi; Hitomi Sezaki; Yusuke Kawamura; Tetsuya Hosaka; Mariko Kobayashi; Satoshi Saitoh; Yoshiyuki Suzuki; Yasuji Arase; Kenji Ikeda; Hiromitsu Kumada
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

Review 2.  Polymorphisms in the hepatitis C virus core and its association with development of hepatocellular carcinoma.

Authors:  Virginia Sedeno-Monge; Veronica Vallejo-Ruiz; Francisca Sosa-Jurado; Gerardo Santos-Lopez
Journal:  J Biosci       Date:  2017-09       Impact factor: 1.826

3.  The Prevalence of Hepatitis C Virus Core Amino Acid 70 Substitution and Genotypes of Polymorphisms Near the IFNL3 Gene in Iranian Patients With Chronic Hepatitis C.

Authors:  Danesh Kadjbaf; Maryam Keshvari; Seyed Moayed Alavian; Ali Pouryasin; Bita Behnava; Shima Salimi; Leila Mehrnoush; Pegah Karimi Elizee; Heidar Sharafi
Journal:  Hepat Mon       Date:  2016-05-03       Impact factor: 0.660

4.  Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions.

Authors:  Hideki Fujii; Atsushi Umemura; Taichiro Nishikawa; Kanji Yamaguchi; Michihisa Moriguchi; Hideki Nakamura; Kohichiroh Yasui; Masahito Minami; Saiyu Tanaka; Hiroki Ishikawa; Hiroyuki Kimura; Shiro Takami; Yasuyuki Nagao; Toshihide Shima; Yoshito Itoh
Journal:  World J Hepatol       Date:  2017-09-08

5.  Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.

Authors:  Kanako Yoshida; Hoang Hai; Akihiro Tamori; Yuga Teranishi; Ritsuzo Kozuka; Hiroyuki Motoyama; Etsushi Kawamura; Atsushi Hagihara; Sawako Uchida-Kobayashi; Hiroyasu Morikawa; Masaru Enomoto; Yoshiki Murakami; Norifumi Kawada
Journal:  Int J Mol Sci       Date:  2017-05-03       Impact factor: 5.923

6.  The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1.

Authors:  Akio Miyasaka; Yuichi Yoshida; Toshimi Yoshida; Akihiko Murakami; Koichi Abe; Ken Ohuchi; Tadashi Kawakami; Daisuke Watanabe; Takao Hoshino; Kei Sawara; Yasuhiro Takikawa
Journal:  Intern Med       Date:  2018-05-18       Impact factor: 1.271

7.  Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.

Authors:  Fumitaka Suzuki; Naoya Hatanaka; Etsuya Bando; Koji Nakamura; Akira Komoto
Journal:  Hepatol Int       Date:  2018-06-09       Impact factor: 9.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.